α-Synuclein (SNCA)

A 140-amino-acid intrinsically disordered protein highly expressed at CNS presynaptic terminals. Best known as the principal protein component of Lewy bodies and Lewy neurites — the intraneuronal inclusions that define parkinsons-disease and related synucleinopathies ¹. Under physiological conditions α-synuclein assists synaptic vesicle recycling and neurotransmitter release; pathologically it converts to β-sheet-rich amyloid fibrils that resist clearance by chaperone-mediated-autophagy and macroautophagy, making it a central node in the loss-of-proteostasis hallmark of brain aging.

Identity

UniProt: P37840 (SYUA_HUMAN)
NCBI Gene: 6622
HGNC symbol: SNCA
Mouse ortholog: Snca (high sequence conservation; widely used in transgenic PD models)
Length: 140 amino acids (canonical human isoform)
Intrinsic disorder: Monomeric α-synuclein is largely unstructured in solution; adopts defined secondary structure only upon lipid-membrane binding or aggregation
Historical alias: NACP (non-amyloid-beta component precursor) — named before its role in PD was established

Domain organization

α-Synuclein is divided into three functionally distinct regions:

Region	Residues	Properties	Function
N-terminal amphipathic helix	1–60	Contains 7 imperfect KTKEGV repeats; adopts α-helical structure on lipid membranes	Lipid binding; membrane curvature sensing; vesicle association
NAC (non-amyloid component)	61–95	Highly hydrophobic; aggregation-prone; forms β-sheet core of amyloid fibrils	Essential for fibril nucleation and elongation; deletion of NAC prevents fibril formation
C-terminal acidic tail	96–140	Intrinsically disordered; rich in acidic residues; contains Ser129 (major phosphorylation site)	Calcium binding; interaction with chaperones; modulates aggregation rate

The NAC region is the critical aggregation nucleus: deletion of residues 71–82 within NAC abolishes fibril formation in vitro. needs-replication (deletion studies conducted primarily in vitro; intracellular aggregation propensity of NAC-deletion mutants is less characterized).

Native function

α-Synuclein is enriched at presynaptic terminals and associates with the cytoplasmic face of synaptic vesicles. Current understanding of its physiological role:

SNARE complex assembly — promotes assembly of the SNARE complex (particularly VAMP2/synaptobrevin), facilitating vesicle priming and fusion during neurotransmitter release unsourced (specific mechanism debated; primary citation for SNARE chaperone function needed)
Vesicle trafficking and pool maintenance — modulates the reserve pool of synaptic vesicles; α-synuclein null mice show subtle deficits in dopamine release kinetics but are otherwise viable and fertile
Lipid membrane binding — the amphipathic N-terminal helix inserts into curved membranes; this interaction modulates membrane curvature and may assist vesicle budding

Native oligomerization state — contested: An influential proposal holds that native α-synuclein exists as a helically folded tetramer resistant to aggregation (Bartels et al. 2011; Bhardwaj et al. 2018), with pathological aggregation requiring prior tetramer-to-monomer conversion. The counter-view holds that native α-synuclein is intrinsically disordered monomer that aggregates directly. The debate remains unresolved. contradictory-evidence — the tetramer hypothesis has not achieved consensus; most mechanistic aggregation studies use purified recombinant monomer.

Pathological aggregation

The transition from functional monomer to cytotoxic aggregates proceeds through several stages:

Monomer (disordered) → Oligomers (soluble; β-sheet-rich; TOXIC) → Protofibrils → Fibrils → Lewy bodies / Lewy neurites

Key mechanistic features:

Toxic species — oligomers, not mature fibrils: Current evidence favors soluble oligomeric intermediates — not mature amyloid fibrils — as the primary toxic species. Oligomers permeabilize membranes, impair mitochondrial function, and disrupt vesicle trafficking. Mature fibrils may sequester toxic oligomers, making their net effect ambiguous. contradictory-evidence — whether fibrils are neutral, protective, or also toxic is unresolved.
NAC-driven β-sheet conversion: Aggregation is nucleated by the NAC region adopting cross-β-sheet geometry. The rate is accelerated by: elevated protein concentration (as in SNCA duplications/triplications), metal ions (Cu²⁺, Fe³⁺), pesticides (rotenone, paraquat), lipid membranes, and seeding by pre-formed fibrils.
Lewy bodies as cellular sinks: Mature Lewy bodies contain hyperphosphorylated (pSer129), ubiquitinated α-synuclein fibrils embedded in a matrix of hundreds of other proteins including chaperones, proteasomal subunits, and lipid droplet components. Their formation may represent a cellular attempt to sequester toxic oligomers ¹.
Clearance resistance: Fibrils and large oligomers cannot enter the chaperone-mediated-autophagy translocation complex (too large to thread through LAMP-2A channel). They must be cleared by macroautophagy (autophagy) or the ubiquitin-proteasome-system, both of which decline with age.

Genetics — SNCA as a PD-causative gene

Missense mutations (autosomal dominant)

The first causal PD gene was identified in 1997: Polymeropoulos et al. found that the A53T missense mutation in SNCA segregated with autosomal dominant PD in Italian and Greek kindreds ². Subsequent mutations identified:

Mutation	Discovery	Clinical notes
A53T (Ala53Thr)	Polymeropoulos 1997 ²	First PD-causative mutation identified; accelerates fibril formation in vitro
A30P (Ala30Pro)	Krüger 1998	Reduces membrane binding; impairs CMA substrate recognition
E46K (Glu46Lys)	Zarranz 2004	Associated with Lewy body dementia phenotype; promotes membrane binding
H50Q (His50Gln)	Appel-Cresswell 2013	Accelerates aggregation; rare
G51D (Gly51Asp)	Lesage 2013	Severe early-onset; attenuates membrane binding and aggregation

All missense mutations accelerate some aspect of the aggregation pathway or impair CMA/autophagy-mediated clearance.

Gene duplications and triplications (dose-dependent disease)

A critical genetic insight came with the demonstration that simple copy-number increases in wild-type SNCA are sufficient to cause PD — and that dose correlates with severity:

SNCA triplication — causes familial PD with unusually early onset (~35 years) and rapid progression including dementia; triplication identified in the Spellman-Muenter kindred ³
SNCA duplication — causes PD with later onset and slower progression than triplication; same SNCA protein, more of it

This dose-response relationship established that α-synuclein accumulation per se — not a mutant protein — is sufficient to cause neurodegeneration, strongly implicating proteostatic failure as central rather than gain-of-toxic-function from a specific mutation ³.

Dimension	Status
Pathway conserved across mammals?	yes — SNCA is conserved in vertebrates
Gene-dose → severity relationship in humans?	yes — duplication vs triplication families directly compared ³
Animal model recapitulation?	partial — SNCA-A53T transgenic mice develop motor dysfunction and inclusions but not overt dopaminergic neurodegeneration matching human PD

α-Synuclein and chaperone-mediated autophagy

Wild-type α-synuclein is a canonical substrate of chaperone-mediated-autophagy (CMA) via a KFERQ-like motif recognized by cytosolic HSC70. Mutant forms (A53T, A30P) interact aberrantly with the LAMP-2A receptor:

Normal (WT) turnover: HSC70 recognizes the KFERQ-like motif in WT α-synuclein → substrate is targeted to LAMP-2A at the lysosomal membrane → translocated into the lysosomal lumen → degraded by cathepsins. CMA accounts for a substantial fraction of α-synuclein turnover under basal conditions.
Mutant α-synuclein blocks CMA (uptake-blocker mechanism): A53T and A30P α-synuclein bind LAMP-2A at the lysosomal surface but cannot be translocated — they occupy the receptor without entering the lumen. This receptor blockade inhibits CMA of all other substrates ⁴. One such collaterally impaired substrate is MEF2D (a neuronal survival transcription factor), whose CMA-dependent degradation is disrupted by both WT and mutant α-synuclein, increasing neuronal vulnerability ⁵.
LAMP-2A decline amplifies the problem: LAMP-2A protein levels fall with age at the lysosomal membrane (see chaperone-mediated-autophagy for mechanism). The combination of rising α-synuclein burden (from impaired clearance) and declining LAMP-2A (from aging) creates a reinforcing proteostatic bottleneck specific to post-mitotic neurons.

Dimension	Status
Pathway conserved in humans?	yes — KFERQ motif and LAMP-2A translocation machinery are conserved
LAMP-2A uptake-blocker mechanism in humans?	partial — established in cell models (Wistar rat lysosomes, PC12 cells, primary neurons; Cuervo 2004); human PD-brain data are correlative (reduced LAMP-2A and HSC70 in PD substantia nigra postmortem)
Replicated independently?	partial — Cuervo 2004 ⁴ is the primary mechanistic study; substantive independent replication in cell/animal models followed

needs-human-replication — The causal chain from mutant α-syn → LAMP-2A blockade → neurodegeneration has not been established prospectively in human subjects.

Prion-like propagation (Braak hypothesis)

A central unresolved question in PD biology is whether α-synuclein pathology spreads through the brain in a prion-like manner — with misfolded α-synuclein acting as a template to convert native protein in connected neurons. Evidence for and against:

For propagation:

Lewy pathology in PD follows a largely stereotyped caudal-to-rostral staging pattern (Braak staging, stages 1–6) consistent with trans-neuronal spread
α-Synuclein fibrils injected into rodent striatum initiate propagating Lewy-like pathology across connected regions
Postmortem analysis of patients who received fetal dopaminergic neuron grafts showed Lewy bodies in grafted cells ~10–16 years post-transplant (Kordower et al. 2008; Li et al. 2008) — suggesting host-to-graft transmission unsourced (Kordower/Li 2008 not yet cited on this wiki; stub candidate)

Against / complicating:

Not all PD brains follow Braak staging; ~6–8% show SNc pathology without lower brainstem involvement (Braak “skippers”)
It is unclear whether spread is trans-neuronal or via extracellular seeding of oligomers/exosomes
The clinical αSyn-SAA biomarker confirms synucleinopathy but cannot track staging in living patients

contradictory-evidence — the prion-like spreading mechanism is the dominant framework but not mechanistically proven in humans.

Therapeutic angles

No disease-modifying therapy targeting α-synuclein has demonstrated efficacy in a well-powered Phase 3 trial as of 2026. Current investigational approaches:

Druggability — tier-2 (re-rated 2026-05-08). No α-synuclein-targeted drug is FDA-approved for any indication; the most advanced candidates (prasinezumab PRX002, cinpanemab BIIB054 — both anti-α-synuclein passive immunotherapies) failed Phase 2 primary endpoints in Parkinson’s disease. The earlier tier-1 assignment reflected the depth of clinical-stage activity targeting α-synuclein in PD (multiple Phase 1–2 immunotherapies, ASO programs, anti-aggregation small molecules), but the strict Open Targets criterion (Approved Drug = true for an aging indication) does not apply, and after the Phase 2 immunotherapy failures the tier-1 designation was no longer defensible. Tier-2 (“high-quality probe”) accurately reflects the current state: well-characterized clinical-stage programs without an approved or efficacious agent. The protein remains a central node in loss-of-proteostasis / disabled-macroautophagy in brain aging.

Approach	Mechanism	Status
Prasinezumab (PRX002/RG7935)	Anti-α-syn passive immunotherapy; targets aggregated forms	Phase 2 — post-hoc signal in fast progressors; overall primary endpoint not met long-term-unknown
Cinpanemab (BIIB054)	Anti-fibrillar α-syn monoclonal	Phase 2 — failed primary endpoint (SPARK trial 2023)
Anti-aggregation small molecules	Various (anle138b, NPT200-11)	Preclinical to Phase 1 dose-response-unclear
LAMP-2A / CMA restoration	Increase CMA receptor to clear substrate	Preclinical only (see chaperone-mediated-autophagy for QX77/CA77.1) needs-human-replication
Gene silencing (ASO/siRNA)	Reduce SNCA expression to lower substrate burden	Phase 1/2 (BIIB101 ASO; SNCA-targeting); readout pending long-term-unknown

Limitations and gaps

Toxic species identity: Whether oligomers, protofibrils, or both are the primary toxic species is unresolved. Most intervention studies target fibrils (immunotherapy) but toxicity may reside upstream. contradictory-evidence
Native tetramer debate: If the tetramer hypothesis is correct, therapies should stabilize the tetramer rather than prevent fibril formation — a distinct mechanistic target. This debate is unresolved. contradictory-evidence
Human CMA causal chain: The LAMP-2A uptake-blocker mechanism ⁴ and MEF2D collateral impairment ⁵ are established in cell models; direct evidence in human PD brain is correlative. needs-human-replication
Propagation mechanism: Cell-to-cell spread is demonstrated in model systems but the mechanism (exosomes, tunneling nanotubes, trans-synaptic fibril transfer) and its quantitative contribution to human disease progression remain unknown. no-mechanism
Braak staging exceptions: ~8% of PD brains do not follow the predicted Braak sequence; the staging does not capture all PD subtypes. contradictory-evidence
Immunotherapy failures: Two Phase 2 trials targeting aggregated α-synuclein failed their primary endpoints. Whether the target hypothesis, the timing of intervention, the choice of epitope, or patient selection explains this is unknown. no-mechanism
SNCA missense mutations — rarity: Most missense mutations (A30P, E46K, H50Q, G51D) are extremely rare; functional inferences about aggregation propensity rely primarily on in vitro biophysics, not patient cohort data. needs-human-replication

Cross-references

parkinsons-disease — primary disease context; SNCA A53T verified-cited; Lewy body neuropathology; gene-dose severity from triplication/duplication
chaperone-mediated-autophagy — canonical CMA substrate; A53T/A30P act as LAMP-2A uptake blockers impairing CMA of all substrates (Cuervo 2004); MEF2D collateral impairment by α-synuclein (Yang 2009); rate-limiting LAMP-2A decline with age
loss-of-proteostasis — hallmark; α-synuclein aggregation as a central example
disabled-macroautophagy — macroautophagy also required for fibril/oligomer clearance; both pathways decline with age
neurodegeneration — parent category
hsc70 — cytosolic chaperone recognizing KFERQ-like motif on α-synuclein for CMA targeting (stub)
lamp-2a — lysosomal membrane receptor blocked by A53T/A30P α-synuclein (stub)
pink1 — AR-PD gene; PINK1/Parkin pathway intersects with mitophagy in same dopaminergic neurons
parkin — AR-PD gene; ubiquitinates α-synuclein (controversial) and mitochondrial substrates
ubiquitin-proteasome-system — alternative clearance pathway for monomeric α-synuclein; impaired by aggregates (stub)
lrrk2 — AD-PD gene; LRRK2 kinase phosphorylates Rab GTPases regulating vesicle trafficking; interacts with α-syn pathology (stub)
braak-staging — caudal-to-rostral staging of Lewy pathology (stub)

Footnotes

spillantini-1997-alpha-synuclein-lewy-bodies · doi:10.1038/42166 · Spillantini MG et al. · immunohistochemistry · Nature 1997;388(6645):839–840 · α-synuclein is the principal protein component of Lewy bodies and Lewy neurites in PD and DLB; demonstrated by specific α-synuclein antibody immunostaining in postmortem human brain · model: human postmortem brain (PD and DLB) · archive: bronze OA, download failed · 8,162 citations · no-fulltext-access ↩ ↩²
polymeropoulos-1997-snca-a53t · doi:10.1126/science.276.5321.2045 · Polymeropoulos MH et al. · genetic linkage + sequencing · Science 1997;276(5321):2045–2047 · A53T missense in SNCA segregating with AD-PD in Italian and Greek kindreds; first identification of a PD-causative gene · n=small kindreds · in-vivo · model: human familial PD · archive: not_oa, no local PDF · 8,128 citations · no-fulltext-access ↩ ↩²
singleton-2003-snca-triplication · doi:10.1126/science.1090278 · Singleton AB et al. · copy-number analysis + sequencing · Science 2003;302(5646):841 · Triplication of the SNCA locus in the Spellman-Muenter kindred causes autosomal dominant PD with early onset (~35 years) and rapid progression including dementia; 2× copy number → more severe disease than duplication, establishing a gene-dose–disease-severity relationship for WT α-synuclein · model: human genetics · archive: not_oa, no local PDF · 4,334 citations · no-fulltext-access ↩ ↩² ↩³
cuervo-2004-alpha-syn-impairs-cma · doi:10.1126/science.1101738 · Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D · Science 2004;305(5688):1292–1295 · Mutant α-synuclein (A53T and A30P) binds the CMA receptor at the lysosomal surface but is not translocated, acting as an uptake blocker that inhibits CMA of all other substrates; WT α-synuclein is a normal CMA substrate · in-vitro + cell culture · model: isolated Wistar rat liver lysosomes; primary cultured neurons; PC12 cells; mice · archive: not_oa, no local PDF · 1,966 citations · no-fulltext-access ↩ ↩² ↩³
yang-2009-mef2d-cma · doi:10.1126/science.1166088 · Yang Q, She H, Gearing M, Colla E, Lee M, Shacka JJ, Mao Z · Science 2009;323(5910):124–127 · MEF2D, a neuronal survival transcription factor, is continuously degraded via CMA through HSC70 binding; both WT and PD-associated mutant α-synuclein disrupt MEF2D–HSC70 interaction, causing cytoplasmic MEF2D accumulation and neuronal death; elevated MEF2D observed in α-synuclein transgenic mice and postmortem PD brains · cell culture + in-vivo · model: primary neurons; PD patient postmortem brain · archive: not_oa · no-fulltext-access ↩ ↩²

🧬 Aging Wiki

Explorer

alpha-synuclein